(FM) Oncología
Departamento académico
![Foto de (FM) Oncología](/img/uploaded/1575D5546D141A10EB89AE669C8B8533.jpg)
![Foto de Instituto Valenciano de Oncologia](/img/noimage_org.png)
Instituto Valenciano de Oncologia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (50)
2024
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Status of head and neck brachytherapy in Spain in 2022
Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 456-460
-
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
Molecular Cancer, Vol. 23, Núm. 1
-
Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort
Radiotherapy and Oncology, Vol. 194
2023
-
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
Frontiers in Immunology, Vol. 14
-
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients
Journal of Translational Medicine, Vol. 21, Núm. 1
-
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: Multicenter, phase Ib dose escalation and expansion study
International Journal of Gynecological Cancer, Vol. 33, Núm. 4, pp. 562-570
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
-
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study
Cancers, Vol. 15, Núm. 11
2022
-
Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study
Journal of Personalized Medicine, Vol. 12, Núm. 11
-
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10
-
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
Cancers, Vol. 14, Núm. 4
-
Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network
Cancers, Vol. 14, Núm. 8
2021
-
Management of advanced ovarian cancer in Spain: an expert Delphi consensus
Journal of Ovarian Research, Vol. 14, Núm. 1
2020
-
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
-
GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain
Oncologist, Vol. 25, Núm. 9, pp. e1339-e1345
-
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
Breast, Vol. 54, pp. 286-292
2019
-
Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study
Medical Oncology, Vol. 36, Núm. 3
-
Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Actas Dermo-Sifiliograficas, Vol. 110, Núm. 6, pp. 448-459